Bilaal.Raja
Company record

XFOR  X4 Pharmaceuticals, Inc

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$281m
Revenue TTM
$16m
Net income TTM
$-90m
Free cash flow
—
Composite score
—
Sector rank
#2651

Valuation

P / E
—
EV / EBITDA
—
EV / sales
10.1
FCF yield
—
Yield vs 10-yr
-37.39pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-568.8%
EBITDA margin
-544.2%
ROE
-58.0%
ROIC
-248.6%
Revenue growth
—

Insider activity, last 90 days

Net open-market
$-0.36m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

CN disorders are rare blood conditions similarly characterized by increased risks of infections and cancer due to abnormally low levels of neutrophils in the body. Net product revenue was $ 1.7 million and $ 2.7 million for the three and six months ended June 30, 2025, respectively. 15 X4 PHARMACEUTICALS, INC. As of June 30, 2026, deferred revenue related to the Norgine Agreement was $ 1.4 million, of which $ 0.8 million was current. 5. …X4 Pharmaceuticals, Inc, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →